More importantly, it is reported that the endogenous NO can down-regulate the expression of tissue factor (TF), the major initiator of the hypercoagulation state in cancer patients.26 Based on these above advantages, establishment of NO-generating agents may augment the EPR effect and the anticancer effects of nanomedicines and meanwhile prevent platelets activation, hypercoagulation and thrombus formation. Here, F3 is linked to cancer.